Clene Inc.
CLNNClene Inc. in brief
Clene Inc. is a listed company in the Biotechnology industry, based in Salt Lake City, Utah, USA. Its market value was $49 M on 14 October 2026, which makes it the 21,385th largest listed company in the world and the 3,868th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $26 M. Robert Dee Etherington is its chief executive. Its largest product and service lines by sales in 2025 were Royalty (40%). Its shares trade under the symbol CLNN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Clene Inc.
Clene Inc. is a Clinical Stage Biopharmaceutical company focused the treatment of neurodegenerative diseases company. The company annual revenue is 68.2 million USD as on 2020. The headquarters is in USA.
Clene Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed Clene Inc.Formerly Chelsea Worldwide Inc..
- 2021
- 💰Record revenue of $1 millionFY2021, the highest of the 6 years on record.
Events of Clene Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,652 (Jan 2022) · #4,505 (Dec 2022) · #4,282 (Jul 2023) · #4,192 (Jan 2024) · #2,104 (Mar 2026) · #3,718 (Aug 2026) · #3,851 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 203.4×
- Price / book
- —
- Free cash flow yield
- -38.1%
- Net margin (TTM)
- -11170.8%
- Operating margin
- -11540.0%
- Return on equity
- —
- Liabilities / assets
- 197.0%
- Net debt
- $13M
- Revenue growth
- -41.2%
- R&D / revenue
- 7005.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | -41.2% | $-23M | $-26M | -13085.0% |
| Dec 2024 | $0M | -47.7% | $-33M | $-39M | -11588.2% |
| Dec 2023 | $1M | +38.3% | $-41M | $-50M | -7615.4% |
| Dec 2022 | $0M | -34.7% | $-48M | $-30M | -6366.0% |
| Dec 2021 | $1M | +242.9% | $-50M | $-10M | -1352.8% |
| Dec 2020 | $0M | — | $-20M | $-19M | -9181.0% |
| Dec 2019 | — | — | $-16M | $-16M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-19M | $0M | $-19M | — | — |
| Dec 2024 | $-21M | $0M | $-21M | — | — |
| Dec 2023 | $-30M | $0M | $-31M | — | — |
| Dec 2022 | $-39M | $5M | $-44M | — | — |
| Dec 2021 | $-35M | $1M | $-36M | $-0.16 | — |
| Dec 2020 | $-19M | $0M | $-19M | $-1.10 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-0.93 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+200.0% on a year earlier), net income $4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations
- Oct 20, 20268-KCurrent reportMaterial agreement
- Oct 19, 20268-KCurrent reportOther events
- Sep 16, 20268-KCurrent reportMaterial agreement · Other events
- Aug 14, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 22, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Shareholder vote
- May 14, 20268-KCurrent reportMaterial agreement · Results of operations
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportMaterial agreement · Other events
Official filings of Clene Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-23 M
- Net income
- $-26 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $18 M
- Total liabilities
- $36 M
- Total equity
- $-18 M
As of December-2025
Top 38 institutional investors in Clene Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Scoggin Management LP | 500,000 | -100,000 (-16.67%) | 3.47% | $2 M | Nov 16, 2026 |
| 2 | Boxer Capital Management, LLC | 477,515 | 0 (0.00%) | 3.32% | $2 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 333,406 | -300 (-0.09%) | 2.32% | $1 M | Nov 13, 2026 |
| 4 | Ensign Peak Advisors, Inc | 321,461 | -26,601 (-7.64%) | 2.23% | $1 M | Nov 12, 2026 |
| 5 | Empery Asset Management, LP | 221,660 | -694,872 (-75.82%) | 1.54% | $1 M | Nov 16, 2026 |
| 6 | Cantor Fitzgerald, L. P. | 140,000 | New | 0.97% | $1 M | Nov 16, 2026 |
| 7 | Citadel Advisors LLC | 114,847 | New | 0.80% | $0 M | Nov 16, 2026 |
| 8 | Geode Capital Management, LLC | 112,569 | +10,354 (+10.13%) | 0.78% | $0 M | Nov 6, 2026 |
| 9 | Shay Capital LLC | 75,809 | New | 0.53% | $0 M | Nov 16, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 73,009 | +15,244 (+26.39%) | 0.51% | $0 M | Nov 13, 2026 |
| 11 | BlackRock, Inc. | 67,551 | +5,992 (+9.73%) | 0.47% | $0 M | Nov 13, 2026 |
| 12 | State Street Corp | 37,901 | +8,100 (+27.18%) | 0.26% | $0 M | Nov 12, 2026 |
| 13 | Parsons Capital Management Inc/ri | 37,243 | 0 (0.00%) | 0.26% | $0 M | Oct 28, 2026 |
| 14 | Peak6 LLC | 30,012 | 0 (0.00%) | 0.21% | $0 M | Nov 13, 2026 |
| 15 | Jane Street Group, LLC | 25,939 | +15,736 (+154.23%) | 0.18% | $0 M | Nov 12, 2026 |
| 16 | Lunt Capital Management, Inc. | 21,287 | -30,973 (-59.27%) | 0.15% | $0 M | Oct 30, 2026 |
| 17 | Morgan Stanley | 19,792 | -66 (-0.33%) | 0.14% | $0 M | Nov 13, 2026 |
| 18 | Northern Trust Corp | 19,723 | 0 (0.00%) | 0.14% | $0 M | Nov 16, 2026 |
| 19 | ADAR1 Capital Management, LLC | 15,000 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 20 | XTX Topco Ltd | 12,724 | New | 0.09% | $0 M | Nov 16, 2026 |
| 21 | Squarepoint Ops LLC | 11,920 | New | 0.08% | $0 M | Nov 9, 2026 |
| 22 | Arax Advisory Partners | 11,140 | 0 (0.00%) | 0.08% | $0 M | Nov 12, 2026 |
| 23 | Penn Davis Mcfarland Inc | 11,000 | 0 (0.00%) | 0.08% | $0 M | Oct 23, 2026 |
| 24 | Two Sigma Investments, LP | 10,115 | New | 0.07% | $0 M | Nov 16, 2026 |
| 25 | Wells Fargo & Company/mn | 5,927 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
Show all 38: investors 26 to 38
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Global Advisers, LLC | 5,609 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 27 | UBS Group AG | 3,228 | +2,877 (+819.66%) | 0.02% | $0 M | Nov 10, 2026 |
| 28 | PNC Financial Services Group, Inc. | 2,735 | 0 (0.00%) | 0.02% | $0 M | Nov 6, 2026 |
| 29 | Atlantic Private Wealth, LLC | 2,205 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 30 | Steward Partners Investment Advisory, LLC | 2,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 31 | Nuveen, LLC | 1,840 | New | 0.01% | $0 M | Nov 10, 2026 |
| 32 | SBI Securities Co., Ltd. | 1,025 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 33 | Osaic Holdings, Inc. | 985 | -70 (-6.64%) | 0.01% | $0 M | Nov 12, 2026 |
| 34 | Group One Trading LLC | 686 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 35 | Royal Bank Of Canada | 300 | -2,700 (-90.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 36 | Jones Financial Companies Lllp | 250 | -4,750 (-95.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 37 | US Bancorp \de\ | 20 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 38 | BNP Paribas Financial Markets | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Clene Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 231,131 | $1 M | 1.6% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 99,589 | $1 M | 0.69% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 46,026 | $0 M | 0.32% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 26,027 | $0 M | 0.18% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 12,397 | $0 M | 0.09% | <0.01% | +25% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 11,366 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 7,401 | $0 M | 0.05% | <0.01% | +53% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 2,986 | $0 M | 0.02% | <0.01% | −59% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,724 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 266 | $0 M | <0.01% | <0.01% | +14% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Clene Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David J. MatlinDirector | Grant or award | +434,451 | $3.280 | $1.4 M | 912,275 | Form 4 |
| filed | Alison MoscaDirector, 10% owner | Grant or awardindirect | +198,171 | $3.280 | $650 K | 478,671 | Form 4 |
| filed | Robert Dee EtheringtonPresident & CEO, Director | Grant or award | +15,244 | $3.280 | $50 K | 55,393 | Form 4 |
| filed | Chidozie Ugwumba10% owner | Sellindirect | -73,296 | $6.200 | $454 K | 103,417 | Form 4 |
| filed | Chidozie Ugwumba10% owner | Sellindirect | -22,177 | $6.750 | $150 K | 176,713 | Form 4 |
| filed | Chidozie Ugwumba10% owner | Sellindirect | -72,884 | $6.800 | $496 K | 198,890 | Form 4 |
| filed | Chidozie Ugwumba10% owner | Sellindirect | -5,795 | $6.010 | $35 K | 271,774 | Form 4 |
| filed | Chidozie Ugwumba10% owner | Sellindirect | -5,736 | $6.080 | $35 K | 277,569 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Clene Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 1,476 shares at $3.39
- : 1,439 shares at $3.88
- : 3,829 shares at $3.92
- : 4,835 shares at $3.87
- : 61,929 shares at $3.91
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Clene Inc. scorecard#
Passes 0 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 14, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median203.4×Price to sales 203.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-38.1%Free cash flow is -38.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$19 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 2
- ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 4
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.83 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-8.6×Operating income -8.6 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-27.30Z-score -27.30 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Clene Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0.2−41.5%100% | 0.3−47.7%100% | 0.7+38.3%100% | 0.5−34.6%100% | 0.7+251%100% | 0.2—100% | — | |
| Cost of revenue | 0.0−38.6%21.5% | 0.1−42.1%20.5% | 0.1+365%18.5% | 0.0−91.0%5.5% | 0.3—40.0% | — | — | |
| Research and development | 14−30.1%7006% | 20−24.7%5865% | 27−16.5%4076% | 32+12.3%6748% | 28+86.9%3930% | 15+59.0%7381% | 9.6—— | |
| General and administrative | 9.2−30.6%4615% | 13−7.7%3891% | 14−14.9%2205% | 17−23.0%3581% | 22+327%3042% | 5.2−23.9%2500% | 6.8—— | |
| Operating expenses | — | — | — | — | 51+148%7013% | 20+25.0%9913% | 16—— | |
| Total costs and expenses | 23−30.4%11642% | 33−18.8%9776% | 41−15.7%6299% | 49−3.6%10334% | 51—7013% | — | — | |
| Operating income | −23—−11542% | −33—−9676% | −41—−6199% | −48—−10234% | −50—−6913% | −20—−9813% | −16—— | |
| Interest and finance income | 0.2−74.2%112% | 0.9−37.7%253% | 1.4+517%212% | 0.2—47.6% | — | — | — | |
| Interest expense and finance costs | 2.7−34.0%1341% | 4.1−10.8%1188% | 4.6+38.3%697% | 3.3+279%697% | 0.9−8.4%120% | 1.0+980%461% | 0.1—— | |
| Net interest income | — | — | — | −3.3—−697% | −0.9—−120% | — | — | |
| Other non-operating income (expense) | −3.1—−1545% | −6.3—−1844% | −9.0−148%−1371% | 18−53.6%3909% | 40+2864%5506% | 1.3+659%652% | 0.2—— | |
| Income before tax | −26—−13087% | −39—−11520% | −50—−7569% | −30—−6325% | −10—−1406% | −19—−9161% | −16—— | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.4−205%−59.2% | 0.4—197% | — | |
| Net income including minority interests | — | — | — | — | −9.7—−1347% | −19—−9358% | −16—— | |
| Net income attributable to shareholders | −26—−13087% | −39—−11520% | −50—−7569% | −30—−6325% | −9.7—−1347% | −19—−9358% | −16—— | |
| Earnings per share, basic | -2.65—— | -5.67—— | -9.43r-0.47—— | -0.46—— | -0.16—— | -1.10—— | -0.93—— | |
| Earnings per share, diluted | — | — | — | — | -0.16—— | -1.10—— | -0.93—— | |
| Shares, weighted average (basic) | 9.9+41.8%— | 7.0+32.5%— | 5.2r105−92.0%— | 65+5.9%— | 62—— | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | 62+252%— | 18+0.8%— | 17—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 5.2−57.3%28.6% | 12−57.8%44.5% | 29+57.2%55.1% | 18−63.5%41.2% | 50r50−15.2%79.7% | 59+574%86.9% | 8.8—59.1% | |
| Short-term investments | — | 0−100%0.0% | 6.2+24.0%11.8% | 5.0—11.2% | 0—0.0% | — | — | |
| Receivables | 0−100%0.0% | 0.1−55.2%0.2% | 0.1−24.3%0.3% | 0.2+286%0.4% | 0.0+133%0.1% | 0.0—0.0% | — | |
| Inventory | 0.0−45.6%0.2% | 0.1+83.8%0.2% | 0.0−14.0%0.1% | 0.0+4.9%0.1% | 0.0−78.5%0.1% | 0.2+582%0.3% | 0.0—0.2% | |
| Other current assets | 0.1r0.1+1.5%0.8% | 0.1−75.9%0.5% | 0.6−2.2%1.1% | 0.6+43.8%1.3% | 0.4r4.2−88.5%0.6% | 3.5r3.5+430%5.1% | 0.7—4.4% | |
| Current assets | 9.0−44.4%49.5% | 16−58.4%59.1% | 39+33.1%74.2% | 29−46.5%65.6% | 55−13.3%86.6% | 63+565%92.3% | 9.5—63.7% | |
| Property, plant and equipment | 6.0−19.5%33.2% | 7.5−19.3%27.4% | 9.3−12.9%17.7% | 11+106%23.9% | 5.2+22.4%8.2% | 4.2−2.2%6.2% | 4.3—29.0% | |
| Right-of-use (leased) assets | 3.1−15.6%16.9% | 3.6−12.6%13.3% | 4.2−9.4%8.0% | 4.6+41.6%10.3% | 3.3+216%5.2% | 1.0−4.8%1.5% | 1.1—7.3% | |
| Total assets | 18−33.7%100% | 27−47.8%100% | 52+17.6%100% | 44−29.4%100% | 63−7.6%100% | 68+359%100% | 15—100% | |
| Accounts payable | 0.9−28.1%4.9% | 1.2−17.6%4.5% | 1.5−50.1%2.9% | 3.0+56.7%6.8% | 1.9+71.1%3.0% | 1.1+26.4%1.6% | 0.9—6.0% | |
| Debt due within a year | — | — | — | — | — | 5.9—8.7% | — | |
| Current liabilities | 11+4.7%59.4% | 10−59.4%37.6% | 25+82.8%48.4% | 14+130%31.1% | 6.0−48.4%9.6% | 12+170%17.1% | 4.3—29.0% | |
| Lease liabilities (non-current) | 3.3−21.3%17.9% | 4.1−15.7%15.1% | 4.9−11.8%9.4% | 5.6+27.2%12.5% | 4.4+145%6.9% | 1.8+24.5%2.6% | 1.4—9.6% | |
| Total liabilities | 36−1.3%197% | 36−7.1%132% | 39−5.6%74.4% | 41−18.2%92.7% | 50−25.7%80.0% | 68+580%99.5% | 10.0—67.2% | |
| Retained earnings | −308—−1700% | −282—−1032% | −243—−464% | −193—−434% | −163—−259% | −154—−225% | −70—−468% | |
| Shareholders' equity | −18—−97.0% | −8.9−166%−32.4% | 13+314%25.6% | 3.2−74.3%7.3% | 13+3594%20.0% | 0.3—0.5% | −68—−456% | |
| Total liabilities and equity | 18−33.7%100% | 27−47.8%100% | 52+17.6%100% | 44−29.4%100% | 63−7.6%100% | 68+359%100% | 15—100% | |
| Shares outstanding | 11+34.1%— | 8.1+26.0%— | 6.4r128−91.4%— | 75+20.0%— | 62+4.7%— | 60+243%— | 17—— | |
| Cash-flow statement | ||||||||
| Share-based compensation | 6.4−19.8%3191% | 8.0−12.8%2325% | 9.1+7.1%1394% | 8.5−31.3%1800% | 12+1527%1713% | 0.8+90.7%369% | 0.4—— | |
| Cash from operating activities | −19—−9273% | −21—−6236% | −30—−4613% | −39—−8248% | −35—−4789% | −19—−9189% | −13—— | |
| Capital expenditure | −0.0—−19.5% | −0.0—−4.4% | −0.3—−50.5% | −5.2—−1095% | −1.3—−184% | −0.4—−188% | −0.3—— | |
| Cash from investing activities | −0.0−101%−19.5% | 6.3—1847% | −1.5—−229% | −10—−2149% | −1.3—−184% | −0.4—−188% | −0.3—— | |
| Shares issued | — | — | — | 11—2423% | 0—0.0% | — | — | |
| Cash from financing activities | 12—5759% | −1.5−104%−447% | 42+144%6447% | 17−36.4%3647% | 27−61.0%3750% | 70+1164%33754% | 5.5—— | |
| Exchange-rate effect on cash | — | — | — | — | −0.1−132%−11.8% | 0.3—131% | −0.0—— | |
| Change in cash | −7.0—−3483% | −17−259%−4873% | 10—1604% | −32—−6756% | −8.9−118%−1235% | 50—24508% | −8.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.2+11.2%100% | 0.1+273%100% | 0.1+233%100% | 0.0−81.5%100% | 0.1*−15.4%100% | 0.0−82.8%100% | 0.0−70.3%100% | 0.1+11.0%100% | 0.1*−46.5%100% | 0.1—100% | 0.1—100% | 0.1—100% | 0.2*—100% | |
| Cost of revenue | 0.1+97.4%31.5% | 0.0—28.6% | 0.0—40.0% | 0−100%0.0% | 0.0*+27.8%29.9% | 0−100%0.0% | 0−100%0.0% | 0.0+25.0%24.7% | 0.0*−52.6%19.8% | 0.0—20.7% | 0.0—19.8% | 0.0—21.9% | 0.0*—22.4% | |
| Research and development | 14−2.3%5777% | 4.4+26.6%7941% | 3.5−1.2%3857% | 0.3−77.8%2193% | 5.5*−1.2%7147% | 3.5−21.4%23420% | 3.5−15.3%13015% | 1.5−74.8%1828% | 5.6*−16.6%6119% | 4.5—5139% | 4.2—4560% | 5.9—8040% | 6.7*—3925% | |
| General and administrative | 7.7−25.9%3220% | 1.9−9.8%3464% | 1.9−18.8%2144% | 1.7−34.2%11647% | 2.0*−35.3%2657% | 2.2−37.0%14333% | 2.4−28.3%8804% | 2.7−22.3%3279% | 3.2*−6.8%3473% | 3.4—3923% | 3.3—3642% | 3.4—4685% | 3.4*—1994% | |
| Total costs and expenses | 21−12.1%9029% | 6.4+13.1%11434% | 5.4−7.7%6041% | 2.1−50.1%13840% | 7.6*−13.4%9834% | 5.7−28.3%37753% | 5.9−21.3%21819% | 4.2−55.3%5132% | 8.7*−13.4%9611% | 7.9—9083% | 7.5—8222% | 9.3—12747% | 10*—5941% | |
| Operating income | −21—−8929% | −6.3—−11334% | −5.3—−5941% | −2.1—−13740% | −7.5*—−9734% | −5.6—−37653% | −5.9—−21719% | −4.1—−5032% | −8.7*—−9511% | −7.8—−8983% | −7.4—−8122% | −9.2—−12647% | −9.9*—−5841% | |
| Interest and finance income | 0.2−34.5%80.7% | 0.1+25.0%89.3% | 0.1−11.3%61.1% | 0.0−42.0%313% | 0.0*−63.6%51.9% | 0.0−68.5%267% | 0.1−77.0%230% | 0.1−77.4%100% | 0.1*−76.0%121% | 0.1—146% | 0.3—296% | 0.4—492% | 0.5*—269% | |
| Interest expense and finance costs | 2.9+18.1%1217% | 0.7+2.5%1188% | 0.7+2.4%772% | 0.8+30.1%5273% | 0.7*+44.6%969% | 0.6−36.5%4327% | 0.7−47.0%2515% | 0.6−51.1%751% | 0.5*−57.0%567% | 1.0—1175% | 1.3—1409% | 1.2—1704% | 1.2*—706% | |
| Other non-operating income (expense) | −5.6—−2343% | 10—18325% | −8.1—−8974% | −6.0−281%−40200% | −1.7*—−2248% | −3.1—−20860% | −1.6−357%−5759% | 3.3—4105% | −4.9*—−5378% | −0.2—−197% | 0.6—666% | −1.8—−2532% | −0.2*—−143% | |
| Income before tax | −27—−11271% | 3.9—6991% | −13—−14916% | −8.1—−53940% | −9.2*—−11982% | −8.8—−58513% | −7.4—−27478% | −0.8—−927% | −14*—−14889% | −8.0—−9179% | −6.8—−7456% | −11—−15178% | −10*—−5984% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income attributable to shareholders | −27—−11271% | 3.9—6991% | −13—−14916% | −8.1—−53940% | −9.2*—−11982% | −8.8—−58513% | −7.4—−27478% | −0.8—−927% | −14*—−14889% | −8.0—−9179% | −6.8—−7456% | −11—−15178% | −10*—−5984% | |
| Earnings per share, basic | — | 0.30—— | -1.08—— | -0.69—— | — | -0.85—— | -0.78—— | -0.09—— | — | -1.22—— | -1.06—— | -1.73r-0.09—— | — | |
| Earnings per share, diluted | — | 0.05—— | — | — | — | -0.85—— | — | — | — | — | — | — | — | |
| Shares, weighted average (basic) | 13+27.2%— | 13+27.2%— | 12+30.0%— | 12+32.0%— | — | 10+56.8%— | 9.5+48.3%— | 8.8+37.4%— | — | 6.6—— | 6.4—— | 6.4r128—— | — | |
| Shares, weighted average (diluted) | 15+42.6%— | 15+42.6%— | — | — | — | 10—— | — | — | — | — | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 9.9—44.6% | 9.9+24.8%44.6% | 9.7+32.8%42.0% | 5.9−39.6%27.4% | 5.2−57.3%28.6% | 7.9−45.9%35.5% | 7.3−66.4%32.9% | 9.8−54.8%38.8% | 12−57.8%44.5% | 15—46.4% | 22—53.8% | 22—48.2% | 29—55.1% | |
| Short-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 6.2—13.7% | 6.2—11.8% | |
| Receivables | 0.0—0.2% | 0.0—0.2% | 0.0—0.2% | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.1−55.2%0.2% | 0—0.0% | 0—0.0% | 0.1—0.1% | 0.1—0.3% | |
| Inventory | 0.0—0.2% | 0.0−32.8%0.2% | 0.0−53.2%0.2% | 0.1+42.1%0.2% | 0.0−45.6%0.2% | 0.1−52.3%0.3% | 0.1+114%0.4% | 0.0+2.7%0.2% | 0.1+83.8%0.2% | 0.1—0.4% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Other current assets | 0.2—1.1% | 0.2−20.2%1.1% | 0.2−41.1%0.9% | 0.2−29.5%1.1% | 0.1r0.1+1.5%0.8% | 0.3−61.1%1.4% | 0.4−60.7%1.6% | 0.3−58.4%1.4% | 0.1−75.9%0.5% | 0.8—2.5% | 0.9—2.3% | 0.8—1.8% | 0.6—1.1% | |
| Current assets | 14—65.4% | 14+14.4%65.4% | 15+24.4%64.7% | 13−11.2%60.1% | 9.0−44.4%49.5% | 13−35.7%56.8% | 12−57.1%54.2% | 15−54.3%58.0% | 16−58.4%59.1% | 20—62.4% | 28—69.2% | 32—71.2% | 39—74.2% | |
| Property, plant and equipment | 5.0—22.6% | 5.0−21.0%22.6% | 5.3−20.8%23.1% | 5.7−19.9%26.2% | 6.0−19.5%33.2% | 6.4−20.9%28.5% | 6.7−20.5%30.3% | 7.1−20.1%27.9% | 7.5−19.3%27.4% | 8.0—25.5% | 8.4—20.9% | 8.9—19.6% | 9.3—17.7% | |
| Right-of-use (leased) assets | 2.6—11.7% | 2.6−19.8%11.7% | 2.8−18.4%11.9% | 2.9−16.9%13.5% | 3.1−15.6%16.9% | 3.2−14.6%14.5% | 3.4−14.0%15.2% | 3.5−13.2%13.9% | 3.6−12.6%13.3% | 3.8—12.0% | 3.9—9.7% | 4.0—9.0% | 4.2—8.0% | |
| Total assets | 22—100% | 22−0.7%100% | 23+4.1%100% | 22−14.4%100% | 18−33.7%100% | 22−29.3%100% | 22−45.1%100% | 25−43.8%100% | 27−47.8%100% | 32—100% | 40—100% | 45—100% | 52—100% | |
| Accounts payable | 0.9—3.9% | 0.9−37.0%3.9% | 1.1+37.9%5.0% | 1.3−7.4%6.0% | 0.9−28.1%4.9% | 1.4−18.4%6.1% | 0.8−22.3%3.7% | 1.4−14.1%5.6% | 1.2−17.6%4.5% | 1.7—5.3% | 1.1—2.6% | 1.6—3.6% | 1.5—2.9% | |
| Current liabilities | 17—77.2% | 17+106%77.2% | 4.9−35.9%21.1% | 6.7−37.5%31.1% | 11+4.7%59.4% | 8.3−65.1%37.2% | 7.6−73.0%34.2% | 11−58.9%42.5% | 10−59.4%37.6% | 24—75.5% | 28—69.6% | 26—58.1% | 25—48.4% | |
| Lease liabilities (non-current) | 2.6—11.7% | 2.6−25.3%11.7% | 2.8−24.3%12.2% | 3.0−23.1%13.9% | 3.3−21.3%17.9% | 3.5−19.6%15.6% | 3.7−18.2%16.8% | 3.9−16.9%15.5% | 4.1−15.7%15.1% | 4.3—13.7% | 4.5—11.2% | 4.7—10.5% | 4.9—9.4% | |
| Total liabilities | 37—167% | 37+6.6%167% | 48+55.9%208% | 40+33.6%187% | 36−1.3%197% | 35−2.9%155% | 31−24.9%139% | 30−25.8%120% | 36−7.1%132% | 36—113% | 41—101% | 41—90.5% | 39—74.4% | |
| Retained earnings | −326—−1471% | −326—−1471% | −330—−1431% | −316—−1460% | −308—−1700% | −299—−1340% | −290—−1312% | −283—−1117% | −282—−1032% | −269—−851% | −261—−646% | −254—−563% | −243—−464% | |
| Shareholders' equity | −15—−66.8% | −15—−66.8% | −25—−108% | −19—−86.8% | −18—−97.0% | −12—−55.4% | −8.6—−38.6% | −5.0−217%−19.6% | −8.9−166%−32.4% | −4.1—−13.1% | −0.5—−1.2% | 4.3—9.5% | 13—25.6% | |
| Total liabilities and equity | 22—100% | 22−0.7%100% | 23+4.1%100% | 22−14.4%100% | 18−33.7%100% | 22−29.3%100% | 22−45.1%100% | 25−43.8%100% | 27−47.8%100% | 32—100% | 40—100% | 45—100% | 52—100% | |
| Shares outstanding | 14—— | 14+39.1%— | 13+35.0%— | 12+35.9%— | 11+34.1%— | 10+49.0%— | 9.5+47.1%— | 8.7−93.3%— | 8.1+26.0%— | 6.9—— | 6.4—— | 128—— | 6.4r128—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 4.8−29.7%2015% | 1.1−36.6%1927% | 1.0−23.9%1156% | 1.3−32.6%8747% | 1.4*−24.2%1773% | 1.7−22.2%11353% | 1.4−29.9%5063% | 1.9−3.3%2404% | 1.8*−12.0%1979% | 2.2—2515% | 2.0—2144% | 2.0—2758% | 2.0*—1204% | |
| Cash from operating activities | −17—−6946% | −4.6*—−8245% | −2.6*—−2876% | −4.5—−30187% | −4.8*—−6232% | −4.0*—−26613% | −4.7*—−17570% | −5.0—−6186% | −4.9*—−5346% | −3.0*—−3475% | −6.4*—−6985% | −7.1—−9701% | −7.2*—−4219% | |
| Capital expenditure | — | −0.1*—−91.1% | — | — | −0.0*—−36.4% | −0.0*—−73.3% | 0*—0.0% | 0—0.0% | −0.0*—−1.1% | −0.0*—−1.1% | −0.0*—−2.2% | −0.0—−15.1% | −0.0*—−25.3% | |
| Cash from investing activities | −0.1—−33.6% | −0.1*—−91.1% | −0.0*—−1.1% | 0—0.0% | −0.0*—−36.4% | −0.0*—−73.3% | 0*−100%0.0% | 0−100%0.0% | −0.0*—−2.2% | −0.0*—−1.1% | 6.2*—6866% | 0.1—97.3% | −6.2*—−3654% | |
| Shares issued | — | — | — | — | — | 3.3*+60.4%21773% | 2.3*—8533% | 2.7—3300% | — | 2.0*—2340% | 0*—0.0% | 0—0.0% | — | |
| Cash from financing activities | 18+54.5%7772% | 4.9*+4.8%8688% | 6.3*+197%7032% | 5.2+95.8%34893% | 2.1*−18.1%2688% | 4.6*—30947% | 2.1*+7518%7900% | 2.7—3300% | 2.5*—2778% | −4.1*—−4674% | 0.0*—30.8% | −0.0—−26.0% | −0.0*—−10.6% | |
| Change in cash | 2.0—824% | 0.2*−66.3%386% | 3.7*—4147% | 0.8—5000% | −2.7*—−3553% | 0.6*—4267% | −2.5*—−9433% | −2.3—−2868% | −2.5*—−2736% | −7.0*—−8089% | −0.1*—−54.9% | −7.1—−9711% | −13*—−7819% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Clene Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$0 M60%-50%
- Royalty$0 M41%-20%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Clene Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 2 · Material agreement 9 · New debt 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementShareholder vote | 8-K | |
| Material agreementResults announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting noticeResults announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Clene Inc. compares in Biotechnology
- Market cap$49 M · higher than 26% of 726
- Revenue$0 M · higher than 19% of 647
- Revenue growth-41.2% · higher than 22% of 438
- Price / sales203.4× · lower than 6% of 339
- FCF yield-38.1% · higher than 30% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Clene Inc.🇺🇸 | $49 M | — | — | -41.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 14, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Clene Inc.? Verify and update this profile — free
Show Clene Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.